The company’s EGFR and cMet targeted bispecific has generated early but encouraging signals in lung cancer – however, J&J faces stiff competition.
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.